Article Text

Download PDFPDF
Biological augmentation to promote meniscus repair: from basic science to clinic application—state of the art
  1. Courtney R Carlson Strother1,
  2. Daniel B F Saris1,
  3. Peter Verdonk2,
  4. Norimasa Nakamura3,
  5. Aaron J Krych1
  1. 1Department of Orthopedic Surgery, Mayo Clinic, Rocheser, Minnesota, USA
  2. 2Department of Orthopaedic Surgery, Faculty of Medicine, Edegem, Belgium
  3. 3Osaka Health Science University, Osaka, Japan
  1. Correspondence to Dr Aaron J Krych; krych.aaron{at}mayo.edu

Abstract

Meniscus tears range from acute tears during physical activity to chronic degenerative tears. The role of the meniscus in knee stability, load distribution, knee proprioception and arthritis prevention has been well established, and successful repair of meniscus tears has better clinical outcomes and protection from increased degenerative changes. Advancements in surgical techniques have demonstrated meniscus repair is possible in tears previously deemed unsalvageable. In addition, the use of biological augmentation has improved rates of meniscal healing, and the use of biologics is an active area of investigation. In this article, we review current methods of biological augmentation to promote meniscus healing, including biological injections, concomitant procedures and biological membranes.

  • tears
  • meniscus
  • biologics
  • cell therapy
  • arthroscopy
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors NN and AJK had the idea for this article. CCS performed literature review and drafting of the manuscript. NN and AJK performed literature review and revision of the manuscript. DBFS and PV provided review of the manuscript and contribution to literature review. AJK is the guarantor for this article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests CCS and NN have nothing to disclose. AK reports grants and personal fees from Arthrex, Inc, personal fees from Vericel, and personal fees from JRF Ortho outside the submitted work. PV reports grants and personal fees from Active Implants, Cartiheal, CONMED Linvatec, and DePuy outside the submitted work. DS reports grants and personal fees from JRF Ortho, Smith & Nephew outside the submitted work.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Data availability statement There are no data in this work.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.